IL17A and COVID-19: The authors suggested that IL23/IL-17 axis inhibition might not be harmful in the case of SARS-COV-2 infection.23 In another case report, it was presented that a patient with PsA and hypertension treated with adalimumab rapidly recovered from COVID-19 without complications.